affiliate disclosure · We earn affiliate commission on some vendor links. Audits, scores, and rankings are independent — vendors do not pay for placement and do not see drafts. read more →
The compounded semaglutide market that emerged during the 2022–2024 brand-product shortage is largely closed in 2026. Here's what the FDA shortage status, 503A PCAC restrictions, and telehealth provider pivots actually mean for buyers.
FDA drug shortage database historical entries for semaglutide (Wegovy, Ozempic) from 2022 through April 2026; the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting minutes from October 2024 and April 2026; Section 503A of the Federal Food, Drug, and Cosmetic Act; the public partner-program pages of compounded-GLP-1 telehealth providers (Hims, Ro, Mochi, Henry, Eden); and contemporaneous trade-press coverage through Q1 2026.
Compounded semaglutide is approaching closure as a legal channel in May 2026. The shortage exemption that supported it has wound down on the brand-availability side, and the 503A do-not-compound list now restricts the GLP-1 class on the regulatory-action side. Telehealth providers that built the category in 2022–2024 have either exited the line, pivoted to brand-only prescription, or restructured around different compounds.
The longer version below explains how the legal channel opened, why it's closing, and what the May 2026 status actually is.
Section 503A of the FDCA is the law that lets traditional compounding pharmacies prepare individualized prescriptions for specific patients without going through full new-drug-application review. It exists because clinical practice sometimes requires formulations the brand manufacturer doesn't make.
The 503A exemption comes with conditions. One of them: a 503A pharmacy cannot compound a near-identical version of an FDA-approved drug just because the patient prefers it. The compounded version must serve a clinical need the brand product doesn't meet.
There is a narrow exception. If the brand product is in FDA-confirmed shortage, compounded versions become permissible during the shortage period. This shortage exemption is the door through which compounded semaglutide entered the legal telehealth channel.
Wegovy entered FDA-confirmed shortage in March 2022. The combination of high demand and limited Novo Nordisk manufacturing capacity created a multi-month, then multi-year, shortage. Compounded versions became legally available, and a category of telehealth provider emerged to use that exemption commercially:
Combined monthly active patient base across this category reportedly peaked at hundreds of thousands in 2024.
Three regulatory and market forces are closing the channel simultaneously. They are not coordinated; they happen to compound.
Through 2024 and into 2025, Novo Nordisk completed manufacturing capacity expansions for semaglutide products. The FDA-confirmed shortage status began to wind down as brand product became reliably available again. Once a brand product is no longer in confirmed shortage, the 503A shortage exemption no longer covers compounded versions of that compound.
The shortage status for semaglutide products has been resolved or near-resolved through Q1 2026. Compounded versions that operated under the shortage exemption lose their legal cover when the shortage is formally declared over.
The October 2024 PCAC vote recommended adding tirzepatide to the 503A do-not-compound list, citing safety and efficacy concerns specific to compounded versions during the shortage period. The April 2026 PCAC meeting reaffirmed compounding restrictions on the GLP-1 class as a whole.
The PCAC track does not directly bind compounding pharmacies until the FDA acts on the recommendation, and that process can take months to years. But the policy direction is now clear: the FDA has formally signaled that compounded GLP-1 versions are not in scope for routine 503A use. See our 503A and PCAC analysis for the full mechanism.
Faced with simultaneous pressure on the brand-availability and PCAC tracks, telehealth providers responded differently:
The mass-market compounded-semaglutide telehealth offering of 2024 is not the May 2026 reality. The category exists in narrower patient-specific forms, not as a routine alternative to brand product.
A clean readout of where buyers can legally access semaglutide as of May 2026:
| Channel | Status | Notes | |---|---|---| | Brand prescription (Wegovy, Ozempic) | Available | Standard insurance + cash-pay channels | | Compounded via 503A pharmacy | Severely restricted | Patient-specific clinical justification required; no longer a mass-market option | | 503B outsourcing facility compounded | Restricted | Different regulatory pathway, narrower scope | | Telehealth-compounded mass-market | Largely closed | Providers pivoted to brand-prescription-first | | Trial enrollment | Where available | Mostly closed for new semaglutide trials | | Research-peptide channel | Outside legal access framework | Not a substitute; different legal category entirely |
If you previously accessed compounded semaglutide through a mass-market telehealth provider: the channel that supplied that prescription has likely either narrowed or closed. The brand prescription pathway is the cleanest current alternative where eligible.
If your provider still offers compounded semaglutide: confirm the clinical justification with them. Patient-specific compounded formulations remain legal where the brand product genuinely doesn't meet a clinical need (e.g., dose adjustments not available in brand strengths, allergen avoidance). Routine substitution is no longer covered by the shortage exemption.
If you're considering the research-peptide channel as a substitute: the channels are legally distinct. Research-peptide semaglutide is governed by FDA misbranding authority (see our FDA peptide enforcement timeline), not by 503A. The September 2025 Warning Letter sweep specifically targeted vendors making drug claims for compounded-equivalent products. Vendor compliance posture matters.
Two forward indicators that will move the channel further over 2026–2027:
Re-shortage scenarios. If brand semaglutide re-enters confirmed shortage — manufacturing disruption, demand spike, supply chain event — the 503A shortage exemption could re-open partially for that compound. The April 2026 PCAC reaffirmation makes a partial re-opening narrower than the 2022–2024 window, but the door is not permanently sealed.
Brand pricing competition. The structural reason compounded semaglutide had mass-market demand was price differential against brand. As brand-product list and net prices adjust, the demand pressure on alternative channels (compounded, research-peptide) adjusts with them. This is a market force, not a regulatory one, and harder to predict.
This article addresses the legal-channel status. It does not address:
New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.